NCT07584174

Brief Summary

This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction. Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started May 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
May 2026Jan 2027

First Submitted

Initial submission to the registry

May 7, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 13, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

May 14, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2027

Last Updated

May 18, 2026

Status Verified

May 1, 2026

Enrollment Period

7 months

First QC Date

May 7, 2026

Last Update Submit

May 14, 2026

Conditions

Keywords

extracorporeal shock wave therapypulsed electromagnetic filed therapypelvic floor muscles trainingfemales sexual dysfunction

Outcome Measures

Primary Outcomes (1)

  • Female Sexual Function Index (FSFI) Total Score

    Female sexual function will be assessed using the Female Sexual Function Index (FSFI), a validated self-reported 19-item questionnaire designed to evaluate six domains of female sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain. Individual domain scores are calculated and summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function, while scores below 26.55 are considered indicative of female sexual dysfunction.

    Baseline, Week 8. Week 16

Secondary Outcomes (2)

  • Sexual Quality of Life Scale

    Baseline, week 8, and week 16

  • Pelvic floor muscle strength

    Baseline, week 6 and week 16

Study Arms (3)

ESWT + PFMT

EXPERIMENTAL

Participants will receive low-intensity extracorporeal shockwave therapy and participants will perform a standardized pelvic floor muscle training program

Other: low-intensity extracorporeal shockwave therapyOther: Pelvic floor muscle training

PEMF + PFMT

ACTIVE COMPARATOR

Participants will receive pulsed electromagnetic stimulation combined with the same standardized pelvic floor muscle training program

Other: Pulsed electromagnetic field stimulationOther: Pelvic floor muscle training

PFMT (Control)

OTHER

Participants will receive a standardized pelvic floor muscle training program

Other: Pelvic floor muscle training

Interventions

Extracorporeal shockwave therapy will be delivered using a low-intensity radial shockwave device, administered once weekly for 8 weeks, with each session delivering 1500-2000 shockwave pulses at an energy flux density of 0.05-0.10 mJ/mm² and a frequency of 5-8 Hz. The application will target the perineum and pelvic floor trigger points using a standardized treatment probe with appropriate coupling gel to ensure optimal energy transmission. Each session will last approximately 7 minutes, and intensity will be adjusted based on patient tolerance without exceeding the recommended energy threshold for soft tissue application

ESWT + PFMT

Pulsed electromagnetic field stimulation (PEMF) will be applied to the pelvic floor region for 20-minute sessions, three times weekly day after day for 8 consecutive weeks. Stimulation parameters will include a frequency of 10 Hz, magnetic field intensity of 200 μT, and pulse duration of 250 μs. Treatment sessions will be administered under therapist supervision with participants positioned comfortably in supine crook-lying.

PEMF + PFMT

pelvic floor exercises will be performed for 45 minutes per day, three days per week, over an eight-week period. Prior to beginning participant will be directed to void the bladder and be supine lying with flexed knees and mildly abducted hips. She was then will be guided to contract the PFMs maximally, holding each contraction for 10 seconds. This will be performed 15 times with a 10-second rest interval within contractions. Each session will be consisted of three exercise sets, with each set performed for 15 minutes. Home exercises were prescribed twice daily, providing a total of 45 minutes of training each day

ESWT + PFMTPEMF + PFMTPFMT (Control)

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score \<26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.
  • Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.
  • Symptoms persisting for at least 3 months before enrollment.
  • Ability to understand study procedures and provide written informed consent.
  • Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period

You may not qualify if:

  • Pregnancy or planned pregnancy during the study period.
  • Pelvic surgery within the previous 6 months.
  • Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.
  • Neurological disorders affecting pelvic floor or sexual function.
  • Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.
  • Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.
  • Severe psychiatric disorders or cognitive impairment limiting participation.
  • Menopause or perimenopausal status.
  • Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.
  • Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.
  • Contraindications to ESWT or PEMF including cardiac pacemakers or implanted electronic devices, coagulation disorders, anticoagulant therapy, epilepsy, or metal implants in the pelvic region.
  • Current participation in another clinical trial or receipt of physiotherapy for sexual dysfunction within the previous 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Outpatient clinic, faculty of Physical Therapy, Beni Suef University

Banī Suwayf, Egypt

RECRUITING

Central Study Contacts

Mahmoud Hamada Mohamed Associate Professor, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Outcome assessors will be blinded
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Interventional study, randomized allocation, parallel assignment, three arms, assessor-blinded, treatment purpose, 1:1:1 allocation ratio.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Physical Therapy

Study Record Dates

First Submitted

May 7, 2026

First Posted

May 13, 2026

Study Start

May 14, 2026

Primary Completion (Estimated)

December 15, 2026

Study Completion (Estimated)

January 15, 2027

Last Updated

May 18, 2026

Record last verified: 2026-05

Locations